Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
|Videos|August 10, 2016
The Benefits and Risks of Bilateral Salpingo-Oophorectomy in the Treatment of Ovarian Cancer
Author(s)Maurie Markman, MD
Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.
Advertisement
Advertisement
Related to this article
The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5